Market Report -- In Play (BIIB)

MSN Money - USA
Biogen Idec: New pharmacoeconomic data on Tysabri demonstrate significant reduction in steroid use and hospitalizations in patients with MS Co and Elan (ELN ...
See all stories on this topic

Biogen, Elan present positive phase 3 Tysabri data for MS ...
Forbes - NY,USA
LONDON (AFX) - Biogen Idec and Elan Corp said conference data presented today shows Tysabri, the companies' multiple sclerosis drug, significantly reduces ...
See all stories on this topic

---

fampridine

Experimental drug lets man walk again
London Free Press - Canada
... opportunity. The drug, Fampridine, was designed to allow signals from the brain to cross injured areas in the spinal cord. Bannon ...

---

tysabri

Health Canada Grants Approval of Tysabri(TM) (Natalizumab) for the ...
DG News - USA
... Idec Canada and Elan Corporation, plc announced today that following a priority review process, Health Canada has granted approval to Tysabri(TM) (natalizumab ...

Tysabri Cleared in Canada
TheStreet.com - USA
By Althea Chang. Canadian regulators approved the multiple sclerosis drug Tysabri for cases of the disease when other treatments are ineffective. ...
See all stories on this topic

Elan Up On Tysabri Acceptance
newratings.com - USA
1409 GMT [Dow Jones] Elan's (ELA.LN) acceptance of Tysabri by Health Canada was expected, say analysts. Bloxham Stockbrokers notes ...
See all stories on this topic

---

rituximab Multiple Sclerosis

Biogen Gains Rights To UCB's CDP323 In $200M Partnership
BioWorld Online - Atlanta,GA,USA
... the 2006 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in ... its development pipeline for MS, the firm has Rituxan (rituximab), a B ...

---

fampridine acorda

Treatments for Depression Reviewed by NeuroInvestment
Genetic Engineering News (press release) - New Rochelle,NY,USA
... the status of the Corcept Corlux program; and the stunning rise of Acorda (NASDAQ: ACOR) in the wake of its successful Phase III trial for Fampridine-SR in MS. ...

Acorda Therapeutics Announces $31.5 Million Financing
PharmaLive.com (press release) - Newtown,PA,USA
... zanaflexcapsules.com. Acorda's lead clinical stage product, Fampridine-SR, recently completed a Phase 3 study in people with MS. The Company's ...

___________________________________________________________
Tysabri Neurologists and Infusion Centers

To find Tysabri-enrolled neurologists and infusion centers near you, call:
MSActiveSource at 1-800-456-2255 and give them your ZIP Code. They should be able to identify two or three options closest to you. You can also click on one of the maps listed below for our accumulated list.

If the person at MSActiveSource is unable to help you, please ask for a supervisor, and then email us at admin@mspatientsforchoice.org with a report of what you found (including the names and telephone numbers of the neurologists and infusion centers so that we can continue to build our own data base, and any problems you may have had in accessing the data). Please encourage your friends to do the same, including reporting the information to us at: admin@mspatientsforchoice.org. In time, we should have a reasonably good data base of TOUCH-enrolled neurologists and infusion centers.

To locate a neurology practice and/or infusion center nearest you, click on one of the maps listed below.

Important: Neurology practices that have not yet been confirmed as TOUCH-enrolled are marked with an asterisk ( * ). You will need to call these practices and confirm either that they have completed the TOUCH enrollment process, or determine the date they are scheduled to complete the TOUCH enrollment process. We ask that you then email us at admin@mspatientsforchoice.org so that we can update our website.

http://www.mspatientsforchoice.org/tyavail.htm